TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in serum hymecromone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visual analog scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: success rate of IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Hamilton Depression Rating Scale-17 (HAMD-17) score from baseline to 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with remitters and non-remitters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days Lost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neurodevelopmental abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal growth and metabolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hearing dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Use and Sexual Activity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of patients who completed the program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Nerve block success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ad libitum meal intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in cognitive impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: quantity of bacteraemia in central blood stream
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: quality of bacteraemia in central blood stream
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Joint count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PASI75 responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting at Least One Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting at Least One Treatment Emergent Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: trans-aortic gradient reduction ≥ 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage Distribution of Cormack-Lehane Grading System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Teeth With Anatomic Form Graded as A or B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Teeth Scored as A or B for Color Match
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Teeth With Marginal Integrity Graded A, B1 and B2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving good or moderate EULAR response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bech (6-item HAMD-17) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: incidence of events of clinical interest
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Best-corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Surgical Site Infection Post-surgery Days 1 to 3
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade of Wound Healing and Severity of Surgical Site Infections Post-surgery Days 1 to 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Fully Compliant Participants
Endpoint domain: Resource use
Primary endpoint: 5 year actuarial freedom from biochemical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % change in WBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: % change in ANC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in pAKT (S473) Immunohistochemistry (IHC) Score From Baseline to Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of ABT-384 and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamics biomarkers of drug effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Flow-mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bacterial infection with biofilm formation in vaginal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: School-readiness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Well Controlled Participants as Per GOAL Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the severity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the severity of discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changing the frequency of undesirable reactions
Endpoint domain: Adverse events/effects
Primary endpoint: coagulation factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: development of sepsis and infections
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral blood flow (CBF) on Admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral blood volume (CBV) on Admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean transit time (MTT) on Admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain Visual Analog Scale Score at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Visual Analog Scale Score at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Visual Analog Scale Score at Day 56
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in MRSA Sputum Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Oxygenation (PaO2/FiO2 ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient-provider communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Predictive accuracy of machine learning for COVID-19 outcome
Endpoint domain: Mortality/survival
Primary endpoint: Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Virologic Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate based on global assessment of effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to EGPA remission and recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants displaying ongoing engagement with DLC
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Maternal Participants With Adverse Events (AEs) Within 1 Month After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Infant Participants With Any AE Within 1 Month of Age
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Infant Participants With Specific Birth Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in abdominal surface temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in fetal heart activity tracings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects without surgical biopsy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose (MTD) of TQ-B3139
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting toxicity(ies) (DLT[s]) of TQ-B3139
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day transplant-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence, frequency, severity, seriousness and relatedness of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate in completing the procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Motility index (MI) decrease after codeine treatment vs. placebo treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vasopressor and Ventilator-free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the subpulmonary ITS at effort >20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantitative UDT results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of fracture reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Perineum pain score following childbirth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative damage to lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stimulated C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: absolute change in intramyocellular lipid quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean rank stool consistency (MRSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Portal vein pulsatility fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change of Triglyceride (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Biomarker Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Using the VAS and EQ-5D-3L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative propofol Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of total radioactivity in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovery of total radioactivity in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of radioactivity in expired air
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma AT1001 pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma total radioactivity pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ChAd63 RH5
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of participants eligible
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who enroll
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of time for recruitment activities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of activity sessions attended by participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant retention rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Injuries and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of No or Mild colonic spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of freezing episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in postprandial GLP-1 secretion 1 week after implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in postprandial GLP-1 secretion 26 weeks after implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in postprandial GLP-1 secretion 52 weeks after implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in postprandial GLP-1 secretion 3 weeks after explantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in transcriptional pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LN inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Executive Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Memory Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neuropsychiatric inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Meaningful change in Total score on Fibromyalgia Impact Questionnaire (FIQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fidelity of Treatment Implementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Independent Completion of Steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decrease in the number of contaminated urine cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient Health Questionnaire Depression Subscale (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinician-Administered PTSD Scale Severity Score (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Listening Effort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PUFA Levels in Normal and Metastatic Breast Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PUFA Levels in Plasma Pre and Post Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PUFA Levels in Red Blood Cells Pre and Post Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of MBSR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of MBSR
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Leg Extensor Muscle Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Migraine Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum observed serum concentration (Cmax) of guselkumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) from time 0 to 70 days of guselkumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of Pemetrexed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients That Completed at Least 6 Courses of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients Experienced Grade >=3 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: NIRS oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuroprotective effects of CET on frontal and temporal brain structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effects of CET on fronto-temporal brain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Durability of CET effects on cognition and functional outcome at 1 year post-treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Thrombotic occlusion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of gastro-intestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: proportion of patients with severe vitamin D deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Urine Protein-to-Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Urine Albumin-to-Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cessation of fit within ten minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain sensitivity during lumbar puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Weekly Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Gastric antral vascular ectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Scapular Proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Muscle Activation During Scapular Proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal analog Pain Scores on rest and movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants experiencing dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Mean wheal diameter of skin prick test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Renal function (Creatinine clearance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in depressive scores (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Urinary Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of children walking or driven by car to school
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: New grade 3 or 4 adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: osteoporosis treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milk Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Device Effect (SADE)-free rate
Endpoint domain: Adverse events/effects
Primary endpoint: Pre-Op Numeric Rating Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Op Numeric Rating Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-Op Numeric Rating Scale for Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-Op Numeric Rating Scale for Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Curve for Adenosine Diphosphate (ADP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life at baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subject's Assessment of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Norepinephrine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year Disease Free Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Intensity of brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to onset of surgical anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in overall severity of clinical picture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global assessment of efficacy by the patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of low flow events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Wake Time After Sleep Onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: rate of overall recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of bleeding
Endpoint domain: Adverse events/effects